ZYCLARA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZYCLARA (ZYCLARA).
Imiquimod acts as an immune response modifier. It activates toll-like receptor 7 (TLR7), leading to the production of cytokines such as interferon-alpha, interleukin-12, and tumor necrosis factor-alpha, which stimulate both innate and adaptive immune responses.
| Metabolism | Imiquimod is metabolized primarily via oxidative pathways, with CYP1A2 and CYP2A6 as the main cytochrome P450 enzymes involved. It is also conjugated to form glucuronide and sulfate metabolites. |
| Excretion | Renal: 80% as unchanged drug; Fecal: <15% as metabolites; Biliary: minimal (<1%) |
| Half-life | Terminal elimination half-life: 27 hours (range 22-33 hours) following topical application; clinical context: allows once-daily dosing |
| Protein binding | Imiquimod: ~99% bound to plasma proteins (albumin and α1-acid glycoprotein) |
| Volume of Distribution | Volume of distribution: not clinically determined after topical application; systemic absorption minimal (<1% of applied dose); Vd not applicable |
| Bioavailability | Topical: systemic absorption <1% of applied dose (mean 0.2-0.9%); oral: not available |
| Onset of Action | Topical: Clinical improvement (reduction in actinic keratosis lesions) typically observed within 4 weeks of once-daily application |
| Duration of Action | Duration of action: Not well defined; treatment course is 2-4 weeks; lesion clearance continues for up to 8 weeks post-treatment; repeat cycles may be needed |
Apply a thin layer to the affected area once daily at bedtime for 2 weeks (for actinic keratosis) or up to 16 weeks (for superficial basal cell carcinoma). Not for ophthalmic, oral, or intravaginal use.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use is not recommended for patients under 18 years. |
| Geriatric use | No specific dosage adjustment required; clinical studies included patients aged 65 and older with no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZYCLARA (ZYCLARA).
| Breastfeeding | It is unknown if imiquimod is excreted in human milk. M/P ratio not available. Due to minimal systemic absorption from topical application, the risk to the nursing infant is likely low; however, caution is advised. Use on the breast area should be avoided to prevent infant contact. |
| Teratogenic Risk | Imiquimod (ZYCLARA) is pregnancy category C. Systemic absorption is minimal following topical application; however, animal studies have shown some fetal effects at high doses. First trimester: Limited data, but risk cannot be excluded; avoid use unless clearly needed. Second and third trimesters: No known specific risks from topical use; may be used if potential benefit justifies potential risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to imiquimod or any component of the formulation"]
| Precautions | ["Severe local skin reactions may occur, including erythema, erosion, excoriation, flaking, and edema, which may require discontinuation.","Not recommended for use in immunocompromised patients due to unknown efficacy and safety.","Avoid exposure to sunlight or artificial UV light (tanning beds) while using ZYCLARA.","Use with caution in patients with autoimmune diseases as imiquimod may exacerbate these conditions.","Systemic flu-like symptoms (e.g., malaise, fatigue, fever, myalgia) may occur and should be monitored."] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring is required for maternal use of topical imiquimod. Monitor maternal application site for local skin reactions. In case of systemic side effects (rare), monitor accordingly. |
| Fertility Effects | No known effects on human fertility from topical use. Animal studies at high systemic doses showed some impairment of fertility; however, minimal systemic absorption with topical application suggests negligible impact. |